Skip to main content

Table 2 Analysis of Supplement Use by Age Range

From: Characterization of vitamin D supplementation and clinical outcomes in a large cohort of early Parkinson’s disease

Age at Diagnosis

Statistics

No Supp (N = 511)

MVI (N = 322)

VitD (N = 42)

VitD + MVI (N = 68)

p-value

< 50

Freq (%)

91 (70%)

35 (27%)

1 (1%)

2 (2%)

 

Mean (SD)

44.04 (4.54)

44.63 (5.07)

45.00 (NA)

46.50 (3.54)

0.83

50–59

Freq (%)

182 (58%)

106 (34%)

10 (3%)

17 (5%)

 

Mean (SD)

54.85 (2.73)

54.87 (2.96)

56.70 (3.09)

56.06 (2.88)

0.08

60–69

Freq (%)

164 (46%)

139 (39%)

23 (6%)

30 (9%)

 

Mean (SD)

63.81 (2.90)

64.12 (2.85)

64.83 (3.16)

64.13 (2.76)

0.42

≥70

Freq (%)

74 (52%)

42 (29%)

8 (6%)

19 (13%)

 

Mean (SD)

73.54 (3.21)

73.29 (2.62)

72.38 (1.06)

73.37 (3.92)

0.78